Clinical Trial Update: Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating adjuvant capecitabine in high-risk pseudomyxoma peritonei patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pseudomyxoma Peritonei

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Pseudomyxoma Peritonei | Phase 2 | Status: UNKNOWN